Loss of Gene Activity Linked to Development of AD
By LabMedica International staff writers Posted on 06 Jun 2018 |
Image: The structure of the BMI1 (B lymphoma Mo-MLV insertion region 1 homolog) protein (Photo courtesy of Wikimedia Commons).
A team of Canadian neurodegenerative disease researchers has identified a gene and its protein product that appear to be linked to the development of late-onset sporadic Alzheimer’s disease (AD), the most prevalent form of dementia.
Investigators at Université de Montréal (Canada) had discovered several years ago that mutations of the BMI1 (B lymphoma Mo-MLV insertion region 1 homolog) gene in mice triggered accelerated and pathological aging of the brain and eyes.
In a recent study, which was published in the May 29, 2018, issue of the journal Cell Reports, the investigators demonstrated that BMI1 was silenced in AD brains, but not in those with early-onset familial AD, frontotemporal dementia, or Lewy body dementia. BMI1 expression was also reduced in cortical neurons from AD patient-derived induced pluripotent stem cells. BMI1 knockout in human post-mitotic neurons resulted in amyloid beta peptide secretion and deposition, p-Tau accumulation, and neurodegeneration.
Mechanistically, BMI1 was required to repress microtubule associated protein tau (MAPT) transcription and prevent GSK3beta (Glycogen synthase kinase 3 beta) and p53 stabilization, which otherwise resulted in neurodegeneration.
The investigators speculated that restoration of BMI1 activity through genetic or pharmaceutical approaches could represent a therapeutic strategy against AD.
Related Links:
Université de Montréal
Investigators at Université de Montréal (Canada) had discovered several years ago that mutations of the BMI1 (B lymphoma Mo-MLV insertion region 1 homolog) gene in mice triggered accelerated and pathological aging of the brain and eyes.
In a recent study, which was published in the May 29, 2018, issue of the journal Cell Reports, the investigators demonstrated that BMI1 was silenced in AD brains, but not in those with early-onset familial AD, frontotemporal dementia, or Lewy body dementia. BMI1 expression was also reduced in cortical neurons from AD patient-derived induced pluripotent stem cells. BMI1 knockout in human post-mitotic neurons resulted in amyloid beta peptide secretion and deposition, p-Tau accumulation, and neurodegeneration.
Mechanistically, BMI1 was required to repress microtubule associated protein tau (MAPT) transcription and prevent GSK3beta (Glycogen synthase kinase 3 beta) and p53 stabilization, which otherwise resulted in neurodegeneration.
The investigators speculated that restoration of BMI1 activity through genetic or pharmaceutical approaches could represent a therapeutic strategy against AD.
Related Links:
Université de Montréal
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples